Don’t Miss Out on the AI Gold Rush That’s Just Getting Started

“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.

Robert Lenk Biography and Net Worth

Director of Plus Therapeutics

Dr. Robert P. Lenk Ph.D. has been appointed as Independent Director of the Company effective 4/1/2020. Dr. Lenk is President of Link Pharmaceuticals, a pharmaceuticals development consultant to multinational corporations and startups. Previously, Dr. Lenk has served as Chief Scientific Officer of MediVector, Inc.; President of the NanoWorks division of Luna Innovations, Inc.; President & CEO of Therapeutics 2000, Inc.; and Vice President of Research & Development at Argus Pharmaceuticals. Dr. Lenk was also a Cofounder of The Liposome Co. and a Staff Fellow of the National Institute of Child Health and Human Development. Dr. Lenk has a PhD and BS from the Massachusetts Institute of Technology.

What is Robert P. Lenk's net worth?: The estimated net worth of Robert P. Lenk is at least $40,105.60 as of November 15th, 2023. Mr. Lenk owns 24,160 shares of Plus Therapeutics stock worth more than $40,106 as of April 23rd. This net worth estimate does not reflect any other investments that Mr. Lenk may own. Learn More about Robert P. Lenk's net worth.
How do I contact Robert P. Lenk?: The corporate mailing address for Mr. Lenk and other Plus Therapeutics executives is 4200 MARATHON BLVD SUITE 200, AUSTIN TX, 78756. Plus Therapeutics can also be reached via phone at 737-255-7194 and via email at [email protected]. Learn More on Robert P. Lenk's contact information.
Has Robert P. Lenk been buying or selling shares of Plus Therapeutics?: Robert P. Lenk has not been actively trading shares of Plus Therapeutics within the last three months. Most recently, on Wednesday, November 15th, Robert P. Lenk bought 1,000 shares of Plus Therapeutics stock. The stock was acquired at an average cost of $1.77 per share, with a total value of $1,770.00. Following the completion of the transaction, the director now directly owns 24,160 shares of the company's stock, valued at $42,763.20. Learn More on Robert P. Lenk's trading history.
Who are Plus Therapeutics' active insiders?: Plus Therapeutics' insider roster includes Marc Hedrick (CEO), Robert Lenk (Director), Greg Petersen (Director), and Andrew Sims (CFO). Learn More on Plus Therapeutics' active insiders.
Are insiders buying or selling shares of Plus Therapeutics?: In the last year, Plus Therapeutics insiders bought shares 9 times. They purchased a total of 43,888 shares worth more than $77,812.49. In the last year, insiders at the sold shares 1 times. They sold a total of 2,068 shares worth more than $4,053.28. The most recent insider tranaction occured on November, 20th when CEO Marc H Hedrick sold 2,068 shares worth more than $4,053.28. Insiders at Plus Therapeutics own 2.3% of the company. Learn More about insider trades at Plus Therapeutics.
Information on this page was last updated on 11/20/2023.

Robert P. Lenk Insider Trading History at Plus Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/15/2023	Buy	1,000	$1.77	$1,770.00	24,160
11/13/2023	Buy	4,000	$1.43	$5,720.00	23,160
11/10/2023	Buy	2,000	$1.45	$2,900.00	19,160
11/8/2023	Buy	5,000	$1.65	$8,250.00	12,961
11/6/2023	Buy	1,395	$1.50	$2,092.50	1,961
9/13/2021	Buy	466	$27.90	$13,001.40	666
8/25/2020	Buy	200	$37.35	$7,470.00	200

Robert P. Lenk Buying and Selling Activity at Plus Therapeutics

Plus Therapeutics Company Overview

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead drug candidate is Rhenium-186Re obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

Today's Range

Now: $1.66

$1.54

$1.75

50 Day Range

MA: $1.86

$1.63

$2.18

2 Week Range

Now: $1.66

$0.97

$5.09

Volume

199,170 shs

Average Volume

31,949 shs

Market Capitalization

$7.10 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.59

Don’t Miss Out on the AI Gold Rush That’s Just Getting Started

From Banyan Hill Publishing | Ad

See how you can invest alongside him